These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19149228)

  • 21. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels.
    Faydaci G; Bilal E; Necmettin P; Fatih T; Asuman O; Uğur K
    Aging Male; 2008 Dec; 11(4):189-92. PubMed ID: 19172550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of prostate cancer in the mediterranean population of Croatia--a thirty-three year retrospective study.
    Spanjol J; Maricić A; Cicvarić T; Valencić M; Oguić R; Tadin T; Fuckar D; Bobinac M
    Coll Antropol; 2007 Mar; 31(1):235-9. PubMed ID: 17598407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in prostate disease symptoms and visits to the general practitioner among three ethnic groups in New Zealand.
    Gray MA; Crampton P; Weinstein P; Nacey JN
    BJU Int; 2004 Jul; 94(1):96-100. PubMed ID: 15217439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Insulin-like growth factor (IGF-1) and the clinical course of prostate cancer, benign hyperplasia and prostatic intraepithelial neoplasia].
    Povelitsa EA; Nabyrov EA
    Vopr Onkol; 2008; 54(5):596-601. PubMed ID: 19069473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia.
    Cannon GW; Mullins C; Lucia MS; Hayward SW; Lin V; Liu BC; Slawin K; Rubin MA; Getzenberg RH
    J Urol; 2007 Feb; 177(2):610-4; discussion 614. PubMed ID: 17222644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prevalence of benign hypertrophy of the prostate in Turkish men hospitalized in urology].
    Oztürk A; Serel TA; Kosar A; Kecelioglu M
    Prog Urol; 2000 Sep; 10(4):568-70. PubMed ID: 11064898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of serum ghrelin levels in prostate cancer.
    Mungan NA; Eminferzane S; Mungan AG; Yesilli C; Seckiner I; Can M; Ayoglu F; Akduman B
    Urol Int; 2008; 80(3):245-8. PubMed ID: 18480624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Epidemiology of cancer of the prostate. Descriptive study].
    Bravo MP; de Palacio A; del Rey Calero J
    Arch Esp Urol; 1990 May; 43(4):349-52. PubMed ID: 1696450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
    Goel T; Garg S
    Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
    Hegarty JM; Wallace M; Comber H
    Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
    Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors.
    Yin M; Bastacky S; Chandran U; Becich MJ; Dhir R
    J Urol; 2008 Mar; 179(3):892-5; discussion 895. PubMed ID: 18207193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and factors predicting the detection of prostate cancer after transurethral resection of the prostate for clinically benign disease.
    Bright EA; Manuel C; Goddard JC; Khan MA
    Urol Int; 2009; 83(2):171-4. PubMed ID: 19752612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
    Schröder FH; Roobol MJ
    Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
    Klepzig M; Jonas D; Oremek GM
    Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
    Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
    Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 15-year followup of a population based prostate cancer screening study.
    Kjellman A; Akre O; Norming U; Törnblom M; Gustafsson O
    J Urol; 2009 Apr; 181(4):1615-21; discussion 1621. PubMed ID: 19233435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.